The meta-analysis by Stubbs reports that neither PRL-raising AP use nor confirmed hyperprolactinemia contributed to the higher prevalence of low bone mass in schizophrenia; however, they conclude that heterogeneity between studies may underlie the absence of association [10]. The gene discussed is PRL; the disease is schizophrenia.